Person:
GÜZEL, MEHMET

Profile Picture
Google ScholarScopusORCIDPublons
Status
Kurumdan Ayrılmıştır
Organizational Units
OrgUnit Logo
Organizational Unit
Job Title
First Name
MEHMET
Last Name
GÜZEL
Name
Email Address
Birth Date

Filters

20182
Reset filters

Settings

Author: DOLAY, KEMAL × Type: Article ×

Search Results

Now showing 1 - 2 of 2
  • Thumbnail Image
    PublicationOpen Access
    The Role of C-Reactive Protein in the Early Prediction of Serious Pancreatic Fistula Development after Pancreaticoduodenectomy
    (2018-01-01T00:00:00Z) MALYA, Fatma Ümit; Hasbahceci, Mustafa; Tasci, Yunus; KADIOĞLU, HÜSEYİN; GÜZEL, Mehmet; Karatepe, Oguzhan; DOLAY, Kemal; MALYA, FATMA ÜMİT; KADIOĞLU, HÜSEYİN; GÜZEL, MEHMET; DOLAY, KEMAL
    Introduction. Despite recent advances in surgical techniques, pancreatic fistulas are common. We aimed to determine the role of C-reactive protein in the prediction of clinically relevant fistula development. Materials and Methods. Data from patients who underwent pancreaticoduodenectomy between 2012 and 2015 is collected. Postoperative 1st, 3rd, and 5th day (POD1, POD3, and POD5) C-reactive protein (CRP) levels, postoperative pancreatic fistula (POPF) development, other complications, length of hospital stay, and mortality were recorded. Results. Of 117 patients, 43 patients (36.8%) developed complications (including fistulas). Of the patients developing fistulas, 21 (17.9%) had POPF A, 2 (1.7%) had POPF B, and 7 (6.0%) had POPF C. POD5 CRP and POD3 CRP were shown to be significantly correlated with mortality and development of clinically relevant POPF (p = 0 001 and p = 0 0001, resp.) and with mortality (p = 0 017), respectively. The development of clinically relevant POPFs (B and C) could be predicted with 90% sensitivity and 82.2% specificity by POD5 CRP cut-off level of 19 mg/dL and with 100% sensitivity and 63.6% specificity by the difference between POD5 and POD1 CRP cut-off level of > 2.5 mg/dL. Conclusion. CRP levels can effectively predict the development of clinically relevant pancreatic fistulas.
  • Thumbnail Image
    PublicationOpen Access
    The correlation between breast cancer and urinary iodine excretion levels
    (2018-02-01) Malya, FATMA ÜMİT; Kadioglu, HÜSEYİN; Hasbahçeci, Mustafa; Dolay, KEMAL; Guzel, MEHMET; Ersoy, YELİZ EMİNE; MALYA, FATMA ÜMİT; KADIOĞLU, HÜSEYİN; DOLAY, KEMAL; GÜZEL, MEHMET; ERSOY, YELIZ EMINE
    Objective To compare urinary iodine excretion levels in patients with breast cancer and control subjects. Methods In this prospective pilot study, patients with breast cancer and normal controls were recruited. Age and menopausal status were recorded. Levels of serum thyroid-stimulating hormone, blood urea nitrogen and creatinine and urine iodine concentration (UIC) were measured. UIC levels were divided into three categories: low (<100 µg/l), normal (100-200 µg/l) or high (>200 µg/l). Results A total of 24 patients with breast cancer and 48 controls were included in the study. There were no statistically significant differences between the two groups with regard to thyroid-stimulating hormone, blood urea nitrogen or creatinine levels. When considered overall, there was no statistical difference in UIC between patients and controls. However, comparisons within each category (low, normal or high UIC) showed a significantly higher percentage of patients with breast cancer had a high UIC compared with controls. Conclusions A high UIC was seen in a significantly higher percentage of patients with breast cancer than controls. UIC may have a role as a marker for breast cancer screening. Further studies evaluating UIC and iodine utilization in patients with breast cancer are warranted.